Concepedia

Markus Trunzer

MT

Statistics

Publications

10

Citations

364

H-Index

10

Active since

2007

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

Novartis (United States)

Markus Trunzer is an author at Novartis (Switzerland) specializing in medicine, bioanalysis, and medicinal chemistry.

ORCID

Top concepts

Publications per year

2007–2024

10

Publications

10

Metabolic Soft Spot Identification and Compound Optimization in Early Discovery Phases Using MetaSite and LC-MS/MS Validation

Markus Trunzer, Bernard Faller, Alfred Zimmerlin · Journal of Medicinal Chemistry · 2008 · 116 citations

CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs

Alfred Zimmerlin, Markus Trunzer, Bernard Faller · Drug Metabolism and Disposition · 2011 · 90 citations

Multispecies Machine Learning Predictions of In Vitro Intrinsic Clearance with Uncertainty Quantification Analyses

Raquel Rodríguez-Pérez, Markus Trunzer, Nadine Schneider et al. · Molecular Pharmaceutics · 2022 · 34 citations

NIBR-LTSi is a selective LATS kinase inhibitor activating YAP signaling and expanding tissue stem cells in vitro and in vivo

Kenji Namoto, Clara Baader, Vanessa Orsini et al. · Cell stem cell · 2024 · 27 citations

, , +10

Discovery of NP3-253, a Potent Brain Penetrant Inhibitor of the NLRP3 Inflammasome

Angela Mackay, Juraj Velcicky, Nina Gommermann et al. · Journal of Medicinal Chemistry · 2024 · 25 citations

Rows per page

1–5 of 10